Text Size

A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00118755
First received: July 1, 2005
Last updated: February 9, 2011
Last verified: February 2011
History of Changes
Results First Received: April 25, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Colorectal Cancer
Interventions: Drug: capecitabine
Drug: Oxaliplatin
Drug: bevacizumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
XELOX Q3W + Bevacizumab

Capecitabine 850 mg/m^2 twice-daily was given orally. Bevacizumab 7.5 mg/kg via 30-90 minute intravenous (IV) infusion was administered on day 1 every three weeks prior to administration of oxaliplatin.

Oxaliplatin 130 mg/m^2 via 2-hour IV infusion was administered on day 1 every 3 weeks.
XELOX Q2W + Bevacizumab

Capecitabine 1500 mg/m^2 twice-daily was given orally. Bevacizumab 5 mg/kg via 30-90 minute intravenous (IV) infusion was administered on day 1 every two weeks prior to administration of oxaliplatin.

Oxaliplatin 85 mg/m^2 via 2-hour IV infusion was administered on day 1 every 2 weeks.

Participant Flow:   Overall Study
    XELOX Q3W + Bevacizumab     XELOX Q2W + Bevacizumab  
STARTED     217     218  
Safety Population     208     211  
COMPLETED     7     3  
NOT COMPLETED     210     215  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
XELOX Q3W + Bevacizumab

Capecitabine 850 mg/m^2 twice-daily was given orally. Bevacizumab 7.5 mg/kg via 30-90 minute intravenous (IV) infusion was administered on day 1 every three weeks prior to administration of oxaliplatin.

Oxaliplatin 130 mg/m^2 via 2-hour IV infusion was administered on day 1 every 3 weeks.
XELOX Q2W + Bevacizumab

Capecitabine 1500 mg/m^2 twice-daily was given orally. Bevacizumab 5 mg/kg via 30-90 minute intravenous (IV) infusion was administered on day 1 every two weeks prior to administration of oxaliplatin.

Oxaliplatin 85 mg/m^2 via 2-hour IV infusion was administered on day 1 every 2 weeks.
Total Total of all reporting groups

Baseline Measures
    XELOX Q3W + Bevacizumab     XELOX Q2W + Bevacizumab     Total  
Number of Participants  
[units: participants]
 		  217     218     435  
Age  
[units: years]
Mean ± Standard Deviation 		  60.6  ± 11.45     60.8  ± 12.17     60.7  ± 11.81  
Gender  
[units: participants]
 		     
Female     89     96     185  
Male     128     122     250  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression-free Survival (PFS)   [ Time Frame: Time to disease progression or death (through follow-up phase) ]
  Show Outcome Measure 1

2.  Secondary:   Overall Survival   [ Time Frame: Time to death (through follow-up phase): Approximate Median of 718 days ]
  Show Outcome Measure 2

3.  Secondary:   Best Overall Clinical Response   [ Time Frame: Through follow-up phase: Approximate Median of 318 days ]
  Show Outcome Measure 3

4.  Secondary:   Duration of Overall Clinical Response (CR or PR)   [ Time Frame: Time to Disease Progression or Death (through follow-up phase): Approximate Median of 302 days ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Hoffmann-La Roche
phone: 800-821-8590


No publications provided


Responsible Party: Disclosures Group, Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00118755     History of Changes
Other Study ID Numbers: ML18491
Study First Received: July 1, 2005
Results First Received: April 25, 2010
Last Updated: February 9, 2011
Health Authority: United States: Food and Drug Administration